Clearance of hepatitis C virus after living-donor liver transplantation in spite of residual viremia on end date of interferon therapy before transplantation

被引:5
作者
Ichikawa, Tatsuki
Nakao, Kazuhiko
Hamasaki, Keisuke
Honda, Takuya
Shibata, Hidetaka
Akahoshi, Mana
Eguchi, Susumu
Takatsuki, Mitsuhisa
Kanematsu, Takashi
Eguchi, Katsumi
机构
[1] Nagasaki Univ, Dept Internal Med 1, Grad Sch Biomed Sci, Nagasaki 8528501, Japan
[2] Nagasaki Univ, Dept Internal Med 1, Dept Transplantat & Digest Surg, Nagasaki 8528501, Japan
关键词
pegylated interferon; liver transplantation; hepatitis C virus;
D O I
10.3748/wjg.v13.i30.4149
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Interferon (IFN) therapy is the only treatment strategy for hepatitis C virus (HCV) infection after liver transplantation (LT), but prophylactic and treatable IFN therapy after LT has been shown to be insufficient due to the adverse effects of IFN and rivabirin. In this paper, we describe the disappearance of HCV after LT without IFN therapy in the presence of residual viremia on the day of LT. We herein report our findings since this is considered an important case for the anti-HCV strategy of post LT. A 60-year old woman with LC and HCC was referred to Nagasaki University Hospital in August 2004. After she underwent LT on February 18, 2005, we injected peg-IFN-alpha-2a the 11th time at 18 A and HCV-RNA was still positive in the serum at LT. The serum HCV-RNA was negative one month after operation and subsequently dissolved 15 mo after operation without IFN therapy. As a result, we speculate that if HCV-RNA is positive while HCV core antigen is negative before LT, then it may lead to clearance of HCV after LT. Therefore long acting peg-IFN-alpha-2a is thus considered a potentially effective agent for the treatment of HCV-related cirrhosis before LT. (c) 2007 WJG. All rights reserved.
引用
收藏
页码:4149 / 4151
页数:3
相关论文
共 16 条
[1]
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C [J].
Abdelmalek, MF ;
Firpi, RJ ;
Soldevila-Pico, C ;
Reed, AI ;
Hemming, AW ;
Liu, C ;
Crawford, JM ;
Davis, GL ;
Nelson, DR .
LIVER TRANSPLANTATION, 2004, 10 (02) :199-207
[2]
HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].
Berenguer, M ;
Ferrell, L ;
Watson, J ;
Prieto, M ;
Kim, M ;
Rayón, M ;
Córdoba, J ;
Herola, A ;
Ascher, N ;
Mir, J ;
Berenguer, J ;
Wright, TL .
JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684
[3]
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence [J].
Bizollon, T ;
Ahmed, SNS ;
Radenne, S ;
Chevallier, M ;
Chevallier, P ;
Parvaz, P ;
Guichard, S ;
Ducerf, C ;
Baulieux, J ;
Zoulim, F ;
Trepo, C .
GUT, 2003, 52 (02) :283-287
[4]
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C [J].
Bizollon, T ;
Pradat, P ;
Mabrut, JY ;
Chevallier, M ;
Adham, M ;
Radenne, S ;
Souquet, JC ;
Ducerf, C ;
Baulieux, J ;
Zoulim, F ;
Trepo, C .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (08) :1909-1913
[5]
Bruno R, 2004, ANTIVIR THER, V9, P491
[6]
Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials [J].
Chalasani, N ;
Manzarbeitia, C ;
Ferenci, P ;
Vogel, W ;
Fontana, RJ ;
Voigt, M ;
Riely, C ;
Martin, P ;
Teperman, L ;
Jiao, J ;
Lopez-Talavera, JC .
HEPATOLOGY, 2005, 41 (02) :289-298
[7]
A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation [J].
Crippin, JS ;
McCashland, T ;
Terrault, N ;
Sheiner, P ;
Charlton, MR .
LIVER TRANSPLANTATION, 2002, 8 (04) :350-355
[8]
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy [J].
Everson, GT ;
Trotter, J ;
Forman, L ;
Kugelmas, M ;
Halprin, A ;
Fey, B ;
Ray, C .
HEPATOLOGY, 2005, 42 (02) :255-262
[9]
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation [J].
Forns, X ;
García-Retortillo, M ;
Serrano, T ;
Feliu, A ;
Suarez, F ;
de la Mata, M ;
García-Valdecasas, JC ;
Navasa, M ;
Rimola, A ;
Rodés, J .
JOURNAL OF HEPATOLOGY, 2003, 39 (03) :389-396
[10]
Hepatitis C virus kinetics during and immediately after liver transplantation [J].
Garcia-Retortillo, M ;
Forns, X ;
Feliu, A ;
Moitinho, E ;
Costa, J ;
Navasa, M ;
Rimola, A ;
Rodes, J .
HEPATOLOGY, 2002, 35 (03) :680-687